Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox

Arnaud Bayle; Antoîne Italiano; Christophe Massard; Jean Yves Blay; Aurélien Marabelle

doi:10.1016/j.ejca.2021.12.008

Related publications

Letter2022

Added therapeutic benefit regarding ESMO-MCBS and the French health technology assessment of drugs granted early access program

Fiona Y.‐V. Pham, Emmanuelle Jacquet, Adrien Monard, Liora Brunel, Jean Yves Blay, Nicolas Albin

Article2013

Transfusion Requirements in Surgical Oncology Patients (TRISOP): a randomized, controlled trial

Juliano Pinheiro de Almeida, F Galas, E Osawa, J Fukushima, Solène Moulin, C Park, Elisângela Pinto Marinho de Almeida, Sílvia Regina Rios Vieira, Jean Louis Vincent, Andrew Rhodes, Martin Balzan, José Francisco Secorun Inácio, Henrique Palomba, R Nakamura, F Bergamin, Ana C. Vieira Sandrini, Ulysses Ribeiro, José Otávio Costa Auler Júnior, Ludhmila Abrahão Hajjar

Article2012

Innovations in Care Delivery to Slow Growth of US Health Spending

Arnold Milstein, Stephen M Shortell

Article2022

Blockchain technology and supply chains: The paradox of the atheoretical research discourse

Qingyun Zhu, Chunguang Bai, Joseph Sarkis

Transportation Research Part E Logistics and Transportation Review

Article2015

2LBA Responding to the cancer crisis: Expanding global access to radiotherapy - a Lancet Oncology Commission

Rifat Atun, David A. Jaffray, Michael Bartoň, Michaël Baumann, Bhadrasain Vikram, Freddie Ian Bray, T.P. Hanna, Felícia Marie Knaul, Y. Lievens, Brian O’Sullivan, David Rodin, Jake Van Dyke, E. Rosenblatt, Maurice Yap, Eduardo Zubizarreta, Marcin Gospodarowicz